PolarityBio's SkinTE received FDA Breakthrough Therapy Designation for treating Wagner Grade 1 Diabetic Foot Ulcers, based on promising Phase II trial results showing 70% wound closure rate.
PolarityBio has achieved interim enrollment in its Phase III COVER DFUS II trial for SkinTE, a regenerative tissue product targeting Wagner 1 diabetic foot ulcers.